# Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults

> **NCT00921947** · PHASE1,PHASE2 · COMPLETED · sponsor: **VaxInnate Corporation** · enrollment: 60 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** VAX102

## Key facts

- **NCT ID:** NCT00921947
- **Lead sponsor:** VaxInnate Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2011-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00921947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00921947, "Comparative Safety and Immunogenicity of 1.0 µg Intramuscular (i.m.) and 2.0 µg Subcutaneous (s.c.) Dosing With VAX102 (M2e-flagellin) Universal Influenza Vaccine in Healthy Adults". Retrieved via AI Analytics 2026-09-21 from https://api.ai-analytics.org/clinical/NCT00921947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*